This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: congenital aplastic anemia NOS, Constitutional aplastic anemia, Inherited aplastic anemia NOS
Constitutional aplastic anaemia NOS is a collective term for anemia due to bone marrow failure of hereditary or congenital cause, used when no specific gene defect has been identified or as a common umbrella diagnosis for several congenital bone marrow failure syndromes. In ICD-10, code D61.0 is used as a code encompassing various congenital bone marrow failure syndromes such as Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome, and 'NOS (not otherwise specified)' applies when a more specific diagnosis has not been established.
The first description of aplastic anemia was made by Paul Ehrlich in 1888. Over the following decades, the concepts of acquired and congenital aplastic anemia began to be distinguished, and specific congenital bone marrow failure syndromes were established as individual diseases, such as Fanconi anemia in 1927 and Diamond-Blackfan anemia in 1938. From the late 20th century, advances in molecular genetics elucidated several molecular mechanisms, including telomere biology, ribosome biogenesis, and DNA damage repair pathways.
In some patients (about 10–15%) with aplastic anemia previously classified as acquired, a congenital genetic predisposition (especially telomere gene mutations) has been found, and the boundary between constitutional and acquired forms is being redefined. In Korea, with the expansion of molecular genetic testing infrastructure, the proportion of constitutional aplastic anemia of unknown cause is gradually decreasing.
Constitutional aplastic anemia (NOS) is not a single cause but a common phenotype of various congenital bone marrow failure syndromes. Causes include ① dyskeratosis congenita and related telomere diseases due to telomere gene mutations (TERT, TERC, DKC1, RTEL1, TINF2, etc.), ② FA gene mutations (Fanconi anemia), ③ ribosomal protein gene mutations (Diamond-Blackfan anemia), ④ SBDS gene mutations (Shwachman-Diamond syndrome), and ⑤ GATA2 mutations (GATA2 deficiency syndrome).
Mutations in genes involved in telomere synthesis and maintenance (TERT, TERC, DKC1, RTEL1, TINF2, WRAP53, NAF1, ACD, ZCCHC8, etc.) cause dyskeratosis congenita and bone marrow failure related to telomere shortening. Constitutional aplastic anemia in this category can present in both children and adults, and is sometimes accompanied by pulmonary fibrosis, liver cirrhosis, and oral mucosal leukoplakia.
When no causative gene is identified despite sufficient molecular genetic testing, it is classified as constitutional aplastic anemia NOS. In this case, the cause may be as yet unknown gene mutations, noncoding region variants, or epigenetic abnormalities.
The inheritance pattern of constitutional aplastic anemia NOS varies with the causative gene. Several inheritance patterns exist, including autosomal dominant (some telomere gene mutations, GATA2 mutations, heterozygous TERT/TERC mutations), autosomal recessive (Fanconi anemia, Shwachman-Diamond syndrome, some telomere genes other than DKC1), and X-linked recessive (dyskeratosis congenita due to DKC1 mutations).
In constitutional aplastic anemia due to telomere gene mutations, shortening of telomere length is the key pathogenesis. Hematopoietic progenitor cells require sufficient telomere length for their high self-renewal capacity, and telomere shortening induces cellular senescence, p53 activation, and apoptosis. Telomere shortening shows an 'anticipation' phenomenon that is amplified with each generation.
In telomere-related constitutional aplastic anemia, homozygous or compound heterozygous mutations cause early-onset bone marrow failure together with the typical phenotype of dyskeratosis congenita (nail abnormalities, oral mucosal leukoplakia, reticular skin pigmentation). Heterozygous mutations may manifest as mild bone marrow failure or pulmonary fibrosis presenting in adulthood.
Constitutional aplastic anemia NOS accounts for about 10–20% of all aplastic anemia. In pediatric aplastic anemia patients, the proportion of congenital causes is higher than in adults. The prevalence of dyskeratosis congenita (telomere-related) is estimated at about 1 in 1 million. The overall incidence of aplastic anemia in East Asia, including Korea, is about 3–5 per 1 million, higher than in Western countries (about 1–2 per 1 million).
The age of onset of constitutional aplastic anemia NOS varies with the cause. Fanconi anemia mainly presents in childhood (5–15 years), Diamond-Blackfan anemia in infancy, and dyskeratosis congenita ranges from childhood to adulthood depending on the subtype. GATA2 deficiency mainly presents as bone marrow failure in adolescence to adulthood.
In Korea, the proportion of aplastic anemia patients in whom a congenital genetic cause is identified is about 10–15%. Dyskeratosis congenita and telomere-related bone marrow failure are diagnosed at a relatively low rate in adult patients, but the diagnostic rate is gradually increasing with the expansion of molecular genetic testing.
Whatever the cause, the final common pathogenesis of constitutional aplastic anemia is a decrease in the number and function of multipotent hematopoietic progenitor cells (HSC/HSPC). This arises from direct cell loss (apoptosis, senescence), reduced proliferative capacity, impaired differentiation, or abnormalities of the hematopoietic supportive environment (bone marrow niche).
The key pathophysiology is the pathway: telomere gene mutation → reduced telomerase function → telomere shortening with each cell division → p53/p21 activation on reaching critical shortening → cell-cycle arrest and cellular senescence/apoptosis → depletion of hematopoietic progenitor cells.
In constitutional aplastic anemia, somatic mutations accumulate over time due to genomic instability. When HLA gene loss or PIG-A mutations occur in some somatic clones, immune-evading clones are formed, which increases the risk of progression to MDS, paroxysmal nocturnal hemoglobinuria (PNH), and AML.
The symptoms of constitutional aplastic anemia are determined by the degree of pancytopenia. Fatigue, pallor, dyspnea, and tachycardia due to anemia are the most common initial symptoms. Bleeding tendency due to thrombocytopenia (bruising, petechiae, gum bleeding, epistaxis) and recurrent infections and fever due to neutropenia occur.
In telomere-related constitutional aplastic anemia, nail abnormalities (nail dystrophy), oral mucosal leukoplakia, and reticular skin pigmentation (the triad of dyskeratosis congenita) may appear. Pulmonary fibrosis (dyspnea, cough), liver cirrhosis (ascites, jaundice), and oral mucosal cancer may occur. GATA2 deficiency may be accompanied by lymphedema, immunodeficiency, and nontuberculous mycobacterial infection.
Patients with constitutional aplastic anemia have an increased risk of MDS, AML, and solid tumors depending on the cause. In telomere-related constitutional aplastic anemia, MDS, AML, pulmonary fibrosis, liver cirrhosis, and head and neck cancer are the main complications.
Depending on the cause, pallor (anemia), petechiae and purpura (thrombocytopenia), nail abnormalities, oral mucosal leukoplakia, skin pigmentation abnormalities, and lymphedema are found. Hepatosplenomegaly and lymphadenopathy may appear depending on the cause and complications (infection, malignancy).
The complete blood count is characterized by pancytopenia (anemia + thrombocytopenia + leukopenia). The anemia is mainly normocytic or macrocytic and accompanied by reticulocytopenia. Elevated HbF may be observed, reflecting hematopoietic stress. Bone marrow examination is characterized by hypocellular marrow and increased fat cells.
Telomere length measurement (flow cytometry or qPCR) confirms shortened telomere length. Flow cytometry may detect a PNH clone (CD55-/CD59- cells). Chromosome DEB/MMC breakage testing is essential to differentiate Fanconi anemia.
Screening for constitutional causes is recommended in all patients with aplastic anemia (especially children and adults under 35). Step 1: detailed assessment of congenital malformations and family history; step 2: DEB/MMC testing (to differentiate Fanconi anemia); step 3: telomere length measurement; step 4: next-generation sequencing-based congenital bone marrow failure gene panel testing.
When there is a family history of aplastic anemia, pulmonary fibrosis, or liver cirrhosis spanning three or more generations, telomere-related constitutional aplastic anemia is suspected. When selecting a hematopoietic stem cell transplantation donor, if a constitutional cause has been identified, there is a risk that a family donor carries the same gene mutation, so molecular genetic confirmation is essential.
Diagnosis of constitutional aplastic anemia NOS consists of excluding acquired causes (drugs, viruses, autoimmunity) and then systematically searching for congenital causes. A multistep testing strategy to identify the causative gene is recommended.
The cause is searched for with a congenital bone marrow failure gene panel (including 22 FA genes, more than 10 telomere genes, GATA2, SBDS, SRP72, ERCC6L2, ANKRD26, EFL1, etc.). If panel testing is negative, whole-exome sequencing (WES) or whole-genome sequencing (WGS) is considered.
Telomere length is measured in each peripheral blood cell subset (lymphocytes, granulocytes, etc.) by flow cytometry (flow-FISH) or qPCR. Telomere shortening below the 1st–10th percentile for age strongly suggests telomere-related constitutional aplastic anemia.
The curative treatment for constitutional aplastic anemia NOS is HSCT. Conditioning intensity, donor selection, and timing of transplantation differ according to the causative gene. In telomere-related constitutional aplastic anemia, toxicity from irradiation and alkylating agents is increased, so RIC is essential. Because pulmonary fibrosis and hepatic complications persist even after transplantation, long-term follow-up is required.
When an immune mechanism accompanies some cases of constitutional aplastic anemia NOS, immunosuppressive therapy based on antithymocyte globulin (ATG) + cyclosporine may be considered. However, in Fanconi anemia and telomere-related constitutional aplastic anemia, the ATG response rate is low and the risk of malignant transformation is high, so caution is required.
Androgens (danazol) have been reported to improve blood counts in telomere-related constitutional aplastic anemia through increased telomerase activity. They are used as bridging therapy before HSCT or as supportive care in patients ineligible for transplantation. Regular transfusion and iron chelation therapy are also central to supportive care.
The prognosis of constitutional aplastic anemia NOS differs greatly by cause. In Fanconi anemia, the 5-year survival rate after RIC-HSCT is 70–90%. In telomere-related constitutional aplastic anemia, pulmonary fibrosis and hepatic complications are major causes of death even after HSCT. In constitutional aplastic anemia of unknown cause, the treatment response is often similar to that of ordinary acquired aplastic anemia.
In patients with constitutional aplastic anemia, the risk of MDS/AML and solid tumors increases depending on the cause. Regular surveillance for malignancy and early treatment are key to improving survival.
After the causative gene mutation is identified, family screening and genetic counseling are performed. When selecting an HSCT donor, carrier status for the same gene mutation must be checked. Carriers of telomere-related mutations are recommended to enroll in regular surveillance programs for the risk of pulmonary fibrosis and liver cirrhosis.
Regular hematologic follow-up, bone marrow and cytogenetic testing for early detection of MDS/AML, smoking cessation (to reduce head and neck cancer risk), alcohol restriction (to prevent hepatic complications), and infection prevention (vaccination, early antibiotic treatment) are recommended.